Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

Abstract

BackgroundStudies have demonstrated that the regulatory role of competitive endogenous RNA (ceRNA) networks is closely related to tumorigenesis, which provides new targets for tumor therapy. In this study, the focus was to explore the ceRNA networks that regulate SLC6A8 expression and their prognosis in non-small cell lung cancer (NSCLC).MethodsFirstly, the Cancer Genome Atlas (TCGA) data combined with immunohistochemical staining was used to compare SLC6A8 expression in NSCLC tissues and normal tissues. Thereafter, samples from the immunohistochemical staining of NSCLC were integrated with clinical follow-up data for prognostic analysis. The Starbase database was employed to search for SLC6A8-targeted miRNAs and lncRNAs, and survival analysis was performed using clinical data from TCGA to obtain SLC6A8 expression and prognosis-related ceRNA networks. Finally, the prognostic and therapeutic prospects of SLC6A8 in NSCLC were further analyzed from methylation sites and the immune microenvironment.ResultsThe study results revealed that SLC6A8 was significantly overexpressed in NSCLC tissues compared to normal tissues, and clinical follow-up data showed that the overexpression group was associated with poor prognosis. In addition, the Starbase data combined with TCGA clinical data analysis demonstrated that the AL513318.2/hsa-miR-26a-5p/SLC6A8 network regulates SLC6A8 overexpression in NSCLC and is associated with poor prognosis. Methylation analysis revealed that 11 methylation sites were closely associated with the prognosis of NSCLC. In addition, the immune prognostic risk model showed that the high-risk group was associated with a poorer prognosis than the low-risk group, despite showing a better immunotherapy outcome.ConclusionIn summary, the AL513318.2/hsa-miR-26a-5p/SLC6A8 network upregulates SLC6A8 expression in NSCLC and is associated with poor prognosis. Therefore it may be a prognostic biomarker of NSCLC and a potential therapeutic target.

Identification of a seven-lncRNAs panel that serves as a prognosis predictor and contributes to the malignant progression of laryngeal squamous cell carcinoma

“…High expression of LINC01385 was correlated with advanced clinical features and poor prognosis of nasopharyngeal carcinoma (NPC), and knockdown of LINC01385 inhibited the proliferation and invasion abilities of NPC cells ( 45 ). Moreover, upregulation of LINC02893 in non-small cell lung cancer is associated with poor prognosis ( 46 ). Based on the bioinformatic analysis results, we speculated that there are potential mutual regulatory relationships among these seven lncRNAs.…”

Immune-Related Long Non-Coding RNA Signatures for Tongue Squamous Cell Carcinoma

“…To the best of our knowledge, the other four lncRNA biomarkers have not been studied in TSCC. However, lncRNA AC104088.1 was significantly overexpressed in non-small cell lung cancer (NSCLC) and suggested as a prognostic biomarker for NSCLC [40]. The expression level of lncRNA LINC00534 was found to be significantly increased in the serum samples of breast cancer patients [41] and also in lung squamous cell carcinoma tissues [42].…”

Long Intergenic Non-Protein Coding RNA 173 in Human Cancers

“…MicroRNAs (miRNAs) are short non-coding RNAs, usually consisting of 19–25 nucleotides, that specifically bind to the downstream target mRNAs to hinder gene degradation or translation [ 61 ]. Meanwhile, miRNAs can regulate the occurrence and development of human cancers by acting as oncogenes or tumor suppressor genes [ 62 ].…”